|About Dr Yap Yoke Yeow|
Dr Yap Yoke Yeow completed his medical training in Universiti Sains Malaysia in 1997 and his Masters in ORL & Head and Neck Surgery in USM in 2004. Since then he served as Consultant ENT Surgeon in Hospital Kuala Lumpur and Hospital Serdang where he was also visiting consultant to the Radiotherapy and Oncology Institute in Hospital Kuala Lumpur. The first ENT Surgeon to obtain the RPSGT (Registered Polysomnographic Technologist) from USA in 2013, he started the first ASEAN Sleep Congress held in Kuala Lumpur in 2012 as President of the Malaysian Society of Otorhinolaryngologists and Head & Neck Surgeons.
He has also conducted numerous courses and training locally and internationally on Sleep Apnea, Sleep Diagnostics, Sleep Surgery, Nasopharyngeal Carcinoma and Surgery for Nasopharyngeal Carcinoma, Allergy and Sinusitis. He chaired the writing of the Consensus Statements in Obstructive Sleep Apnea, Vertigo and Rhinosinusitis for MSOHNS. He also coordinated the Malaysian Head and Neck Cancer Awareness Program from 2009 to 2012 under MSOHNS. Currently he sits on the Subspecialty Committee for the National Specialist Registry for ORL in Malaysia, of which he was the chairman in 2012-2013. Among his notable awards are, the Gold Medal at the 33rd International Exhibition of Inventions, New Techniques and Products at Geneva-Palexpo (patronage of Swiss Government, 2005), the WIPO Award for Best Inventor for the invention of EZEBV Amp at the ITEX (World Intellectual Property Organisaion & MINDS, 2004), MAKNA Cancer Research Award (National Cancer Council, 2005) and National Scientist of Excellence Award (Ministry of Higher Education, 2005).
Education and Fellowship:
MMed (ORL-HNS, USM),
RPSGT (Board of Registered Polysomnographic Technologists, USA)
Research and Publications:
*A Genome Wide Study of Copy Number Variation Associated with Nasopharyngeal Carcinoma in Malaysian Chinese Identifies CNVs at 11q14.3 and 6p21.3 as Candidate Loci.
PLoS One. 2016 Jan 5;11(1):e0145774. doi: 10.1371/journal.pone.0145774. eCollection 2016.
*Identification of Four-Jointed Box 1 (FJX1)-Specific Peptides for Immunotherapy of Nasopharyngeal Carcinoma.
PLoS One. 2015 Nov 4;10(11):e0130464. doi: 10.1371/journal.pone.0130464. eCollection 2015.
*Homozygous Wildtype of XPD K751Q Polymorphism Is Associated with Increased Risk of Nasopharyngeal Carcinoma in Malaysian Population.
PLoS One. 2015 Jun 18;10(6):e0130530. doi: 10.1371/journal.pone.0130530. eCollection 2015.
*HLA-A SNPs and amino acid variants are associated with nasopharyngeal carcinoma in Malaysian Chinese.
Int J Cancer. 2014 Jun 20. doi: 10.1002/ijc.29035
*Distribution and haplotype associations of XPD Lys751Gln, XRCC1 Arg280His and XRCC1 Arg399Gln polymorphisms with nasopharyngeal carcinoma in the Malaysian population.
Asian Pac J Cancer Prev. 2014;15(6):2747-51.
*Clinical significance of plasma Epstein-Barr Virus DNA loads in a large cohort of Malaysian patients with nasopharyngeal carcinoma.
J Clin Virol. 2012 Sep;55(1):34-9. Epub 2012 Jun 26.
*Identification of a functional variant in SPLUNC1 associated with nasopharyngeal carcinoma susceptibility among Malaysian Chinese
Mol Carcinog. 2012 Oct;51 Suppl 1:E74-82. doi: 10.1002/mc.21857. Epub 2011 Dec 27
*Nasopharyngeal Carcinoma Database.
Med J Malaysia. 2008 Sep;63 Suppl C:59-62.
*Epstein-Barr virus latent membrane protein-1 (LMP-1) 30-bp deletion and Xho I-loss is associated with type III nasopharyngeal carcinoma in Malaysia.
World J Surg Oncol. 2008 Feb 15;6:18. doi: 10.1186/1477-7819-6-18.
*Consensus Guideline on Upper Respiratory Tract Infections MSOHNS Consensus Statement
*Consensus Guidelines on Inflammatory Diseases of the Nose MSOHNS Consensus Statement
*Management of Peripheral Vestibular Disorders in Primary Care
MSOHNS Consensus Statement
*Consensus Statement on Management of Obstructive Sleep Apnea in Primary Care MSOHNS Consensus Statement